Search clinical trials for: IDP-121 Lotion

Total 98030 results

Valeant Pharmaceuticals

Unknown

A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Acne Vulgaris
Valeant Pharmaceuticals

Unknown

A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Acne Vulgaris
Bausch Health Americas, Inc.

Completed

Absorption and Systematic Pharmacokinetics of IDP-121 Lotion in Subjects With Acne Vulgaris

Acne

United States
Bausch Health Americas, Inc.

Completed

Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Acne

United States
Bausch Health Americas, Inc.

Completed

Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Acne

United States
Bausch Health Americas, Inc.

Completed

Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects

Atopic Dermatitis

United States
Bausch Health Americas, Inc.

Completed

Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects (301)

Atopic Dermatitis

United States
IDP Discovery Pharma S.L.

Recruiting

A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies (CASSANDRA)

Chronic Lymphocytic Leukemia (CLL) | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Multiple Myeloma (MM) | High Grade B-Cell Lymphoma, Not Otherwise Specified | Double Hit Lymphoma | Triple Hit Lymphoma

Spain
Bausch Health Americas, Inc.

Completed

A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301)

Acne Vulgaris

United States, Canada
Bausch Health Americas, Inc.

Completed

A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302)

Acne Vulgaris

United States, Canada
Bausch Health Americas, Inc.

Completed

A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
Valeant Pharmaceuticals

Unknown

A Study Comparing the Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris

Acne Vulgaris
Bausch Health Americas, Inc.

Recruiting

A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis

Psoriasis

United States, Panama
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

Plaque Psoriasis

United States
Bausch Health Americas, Inc.

Completed

Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
Bausch Health Americas, Inc.

Completed

Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

Plaque Psoriasis

United States
Bausch Health Americas, Inc.

Completed

Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
Bausch Health Americas, Inc.

Completed

Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
Bausch Health Americas, Inc.

Completed

Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
Bausch Health Americas, Inc.

Completed

Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac Cream

Acne

United States
InQpharm Group

Withdrawn

Tolerability and Benefit of IQP-AS-121 on Fatigue and Mental Alertness

Fatigue

Germany
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis

United States
Bausch Health Americas, Inc.

Completed

Absorption and Systematic Pharmacokinetics of Topically Applied IDP-120 Gel

Acne

United States
Bausch Health Americas, Inc.

Completed

Open-Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics of Topically Applied IDP-126 Gel in Comparison With Control Gel

Acne Vulgaris

United States
Massachusetts General Hospital

Completed

Kisspeptin in the Evaluation of Delayed Puberty

Kallmann Syndrome | Hypogonadotropic Hypogonadism | Delayed Puberty | GnRH Deficiency

United States
Merrimack Pharmaceuticals

Terminated

Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib

Colorectal Cancer | Squamous Cell Carcinoma of the Head and Neck | Non-small Cell Lung Cancer

United States
InQpharm Group

Completed

Safety and Efficacy of IQP-LH-101 in Postprandial Heartburn

Postprandial Heartburn

Germany
Heidelberg Pharma AG

Recruiting

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

Multiple Myeloma | Plasma Cell Disorder

United States, Germany, Poland, Hungary
Bausch Health Americas, Inc.
Dow Pharmaceutical Sciences

Completed

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
Bausch Health Americas, Inc.
Dow Pharmaceutical Sciences

Completed

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
InQpharm Group

Completed

Safety and Efficacy of IQP-MM-101 in Reducing Symptoms of Diarrhoea

Diarrhoea

Germany
InQpharm Group

Completed

IQP-PO-101 for the Regulation of Bowel Movement Frequency

Constipation | Irregular Bowel Movement Frequency

Germany
InQpharm Group

Completed

Clinical Benefit of a Mouthrinse for the Treatment of Dentine Hypersensitivity

Dentin Sensitivity

Germany
Valeant Pharmaceuticals

Unknown

Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris

Acne Vulgaris
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris

Acne Vulgaris

United States
University of Wuerzburg
Deutsche Krebshilfe e.V., Bonn (Germany)

Recruiting

I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer (CLERAD-PROBE)

Differentiated Thyroid Carcinoma

Germany
InQpharm Group
Analyze & Realize

Completed

Benefit of IQP-AO-101 for Sleep

Insomnia, Nonorganic

Germany
InQpharm Group

Completed

IQP-CL-101 in IBS Management

Irritable Bowel Syndrome

Germany
Bausch Health Americas, Inc.
Dow Pharmaceutical Sciences

Completed

Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
Bausch Health Americas, Inc.

Completed

Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel

Acne Vulgaris

United States, Belgium, Canada
Bausch Health Americas, Inc.

Recruiting

A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis

Psoriasis

United States, Panama
Galera Therapeutics, Inc.

Completed

A Phase 1 Study of the Safety and Pharmacokinetics of GC4711 (Oral Capsule) Compared to GC4419 (IV Infusion) and GC4711 (IV Infusion) in Healthy Volunteers

Healthy Volunteers

Australia
Arbutus Biopharma Corporation

Recruiting

Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.

Chronic Hepatitis b

New Zealand
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis

Psoriasis

United States
Ratio Therapeutics, Inc.

Completed

Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer

Prostate Cancer

United States
David Bushnell
VA Office of Research and Development

Completed

Combination Targeted Radiotherapy in Neuroendocrine Tumors

Neuroendocrine Tumors

United States
IDEAYA Biosciences

Recruiting

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Breast Cancer | Ovarian Cancer | Prostate Cancer | Pancreas Cancer | Advanced or Metastatic Solid Tumors

United States
Vertex Pharmaceuticals Incorporated

Completed

Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor

Cystic Fibrosis

United States

3

Subscribe